Clover Biopharmaceuticals, Ltd. (2197.HK) Comparison with companies in other sectors?

Clover Biopharmaceuticals, Ltd. has a share price of 1.34B. You can analyze Clover Biopharmaceuticals, Ltd. (2197.HK) competitors across different market sectors through stock heatmaps.

What are 2197.HK's NET and operating margins?

Clover Biopharmaceuticals, Ltd. (2197.HK) operating margin is around -24.76, and net profit margin is approximately -23.52 as of the latest reports.

In what way does 2197.HK's earnings per share (EPS) trend reflect its financial momentum?

Clover Biopharmaceuticals, Ltd. (2197.HK) EPS is -0.79 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Clover Biopharmaceuticals, Ltd. is -0.68, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Clover Biopharmaceuticals, Ltd.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Clover Biopharmaceuticals, Ltd. like P/E which is -0.69, P/B which is -0.38, and PEG which is -0.01. Compare them with sector averages to evaluate if the stock is priced fairly.

Clover Biopharmaceuticals, Ltd.

2197.HK•HKSE

Healthcare

Biotechnology

HK$0.54

HK$-0.03(-5.26%)

Clover Biopharmaceuticals, Ltd. (2197.HK) Fundamental Analysis: Financial Health, Valuation, and Key Ratios

Dive into Apple Inc.’s fundamentals including valuation ratios, profitability, efficiency metrics, and financial health. Use this data to assess long-term investment quality and compare it with sector benchmarks.

EPS (TTM)

$-0.79

P/E Ratio

-0.68

ROE

0.73%

Net Margin

-23.52%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$724.99M

Shares OutstandingTotal number of shares issued

$1.34B

Book Value/ShareNet worth per share

$-1.30

Revenue/ShareAnnual revenue per share

$0.03

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-0.79

Net MarginNet income as percentage of revenue

-2351.51%

Operating MarginOperating income as percentage of revenue

-2475.88%

ROEReturn on shareholders' equity

73.18%

ROAReturn on total assets

-111.16%

ROCEReturn on capital employed

86.87%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$-0.13

Cash/ShareCash and equivalents per share

$0.34

FCF YieldFree cash flow as percentage of market cap

-23.91%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for 2197.HKFinancial Ratios Analysis details for 2197.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for 2197.HKSector Benchmarking details for 2197.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Clover Biopharmaceuticals, Ltd. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Clover Biopharmaceuticals, Ltd.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Clover Biopharmaceuticals, Ltd.'s unique business strengths and challenges.

Key Financial Metrics for Clover Biopharmaceuticals, Ltd.

For Clover Biopharmaceuticals, Ltd., essential financial indicators include EPS -0.79, PE -0.68, and ROE 0.73. These key ratios reveal insights into Clover Biopharmaceuticals, Ltd.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare Clover Biopharmaceuticals, Ltd. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Clover Biopharmaceuticals, Ltd.

Metrics like Net Margin -2351.51% and ROA -111.16% shed light on how well Clover Biopharmaceuticals, Ltd. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Clover Biopharmaceuticals, Ltd. can sustain its operations and continue growing in the future.

Valuation and Market Position of Clover Biopharmaceuticals, Ltd.

Using ratios such as P/B Ratio -0.38 and PEG Ratio -0.01, investors can assess whether Clover Biopharmaceuticals, Ltd. is appropriately valued based on its financials and growth potential. These figures, combined with Clover Biopharmaceuticals, Ltd.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Clover Biopharmaceuticals, Ltd.

Financial health indicators, such as Debt/Equity Ratio -0.05 and Cash Flow $-0.13, provide a snapshot of Clover Biopharmaceuticals, Ltd.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Clover Biopharmaceuticals, Ltd., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Clover Biopharmaceuticals, Ltd.

Investing in Clover Biopharmaceuticals, Ltd. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Clover Biopharmaceuticals, Ltd. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;